Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Dr. Nagendran on Family History, BRCA Status, and Risk

January 20th 2014

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, discusses a study looking at patients' family history, BRCA mutation status, and breast cancer risk.

NewLink Genetics Pursues Dual Cancer Immunotherapy Platforms

January 20th 2014

Harnessing multiple components of the immune system to fight cancer is the focus of NewLink Genetics' clinical pipeline.

Kris Provides Insight Into New Drugs for Lung Cancer

January 16th 2014

Mark G. Kris, MD, from the Memorial Sloan-Kettering Cancer Center, describes the new drugs and other emerging trends in lung cancer.

Dr. Piperdi on Immunotherapy in Lung Cancer

January 15th 2014

Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses the potential of immunotherapy for the treatment of patients with lung cancer.

Second-Line mCRC Data Further Support RAS Testing Before Panitumumab Use

January 14th 2014

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm

January 13th 2014

There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.

Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014

Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014

Novel Agents and Treatment Strategies in MDS

January 9th 2014

Current and Future Treatment Landscape for MDS

January 9th 2014

Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014

Defining and Predicting Response to HMAs in MDS

January 9th 2014

Role of Genetic Testing in Myelodysplastic Syndromes

January 9th 2014

Hypomethylating Agents in the Treatment of High-Risk MDS

January 9th 2014

Treatment Selection for Resistant or Intolerant CML

January 9th 2014

Second-Generation Tyrosine Kinase Inhibitors in CML

January 9th 2014

Frontline Treatment of Chronic Myelogenous Leukemia

January 9th 2014

Discontinuation of Treatment With TKIs in CML

January 9th 2014

Introduction: Treatment Landscape of MDS

January 9th 2014